公开(公告)号：US09409988B2

公开(公告)日：2016-08-09

申请号：US14127416

申请日：2012-06-22

Applicant: Bruno Robert ,  Benedicte Fauvel ,  Gwenael Cheve ,  Aziz Yasri ,  Christel Larbouret ,  Wilhem Leconet ,  Thierry Chardes ,  Christian Larroque ,  Andre Pelegrin

Inventor： Bruno Robert ,  Benedicte Fauvel ,  Gwenael Cheve ,  Aziz Yasri ,  Christel Larbouret ,  Wilhem Leconet ,  Thierry Chardes ,  Christian Larroque ,  Andre Pelegrin

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/32 ,  G01N33/574 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57492 ,  G01N33/6872

Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.

Abstract translation: 本发明涉及抗Ax1抗体及其在诊断和治疗方法中的用途。 更具体地说，本发明涉及对Ax1具有特异性的单克隆抗体，其包含H-CDR1区中包含SEQ ID NO：2的重链可变区，H-CDR2区中的SEQ ID NO：3和SEQ ID NO： 4在H-CDR3区域; 以及包含L-CDR1区中的SEQ ID NO：6，L-CDR2区的SEQ ID NO：7和L-CDR3区的SEQ ID NO：8的轻链可变区。 所述单克隆抗体通过SEQ ID NO：9和SEQ ID NO：10与Ax1的细胞外结构域结合。

公开(公告)号：US06310074B1

公开(公告)日：2001-10-30

申请号：US09573704

申请日：2000-05-18

Applicant: Patrick Depreux ,  Said Yous ,  Gwenael Cheve ,  Gérald Guillaumet ,  Marie-Claude Viaud ,  Carlos Larraya ,  Caroline Bennejean ,  Philippe Delagrange ,  Pierre Renard ,  Carole Descamps-Francois

Inventor： Patrick Depreux ,  Said Yous ,  Gwenael Cheve ,  Gérald Guillaumet ,  Marie-Claude Viaud ,  Carlos Larraya ,  Caroline Bennejean ,  Philippe Delagrange ,  Pierre Renard ,  Carole Descamps-Francois

IPC: A61K3138

CPC classification number: C07D307/79 ,  C07D333/60 ,  C07D471/04

Abstract: The invention relates to compound of formula (I): A—G1—Cy—G2—Cy′—G3—B  (I) wherein: A represents a grouping NR1C(Q)R2, C(Q)NR2R3 or NR1C(Q)NR2R3, B represents a grouping NR1C(Q)R2, NR1C(Q)NR2R3, C(Q)NR2R3, C(Q)OR1, NR1C(Q)OR2 or NR2R3, G1 and G3 represent an optionally substituted alkylene chain, Cy and Cy′, which are different, represent a ring structure or G2 represents a chain and medicinal products containing the same are useful in treating or in preventing melatoninergic disorders.

Abstract translation: 本发明涉及式（I）化合物：其中：A表示NR1C（Q）R2，C（Q）NR2R3或NR1C（Q）NR2R3基团，B表示分组NR1C（Q）R2，NR1C（Q）NR2R3 ，C（Q）NR2R3，C（Q）OR1，NR1C（Q）OR2或NR2R3，G1和G3表示任选取代的亚烷基链，Cy和Cy'不同，表示环结构.G2表示含有 这同样可用于治疗或预防褪黑激素障碍。

公开(公告)号：US20140302041A1

公开(公告)日：2014-10-09

申请号：US14127415

申请日：2012-06-22

Applicant: Bruno Robert ,  Benedicte Fauvel ,  Gwenael Cheve ,  Aziz Yasri ,  Christel Larbouret ,  Wilhem Leconet ,  Thierry Chardes ,  Christian Larroque ,  Andre Pelegrin

Inventor： Bruno Robert ,  Benedicte Fauvel ,  Gwenael Cheve ,  Aziz Yasri ,  Christel Larbouret ,  Wilhem Leconet ,  Thierry Chardes ,  Christian Larroque ,  Andre Pelegrin

IPC: C07K16/30 ,  G01N33/574 ,  C07K16/40

CPC classification number: C07K16/30 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57492

Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.

Abstract translation: 本发明涉及抗Ax1抗体及其在诊断和治疗方法中的用途。 更具体地说，本发明涉及对Ax1具有特异性的单克隆抗体，其包含H-CDR1区中包含SEQ ID NO：2的重链可变区，H-CDR2区中的SEQ ID NO：3和SEQ ID NO： 4在H-CDR3区域; 以及包含L-CDR1区中的SEQ ID NO：6，L-CDR2区的SEQ ID NO：7和L-CDR3区的SEQ ID NO：8的轻链可变区。 所述单克隆抗体通过SEQ ID NO：9，SEQ ID NO：10和SEQ ID NO：11结合Ax1的细胞外结构域。

公开(公告)号：US20140227283A1

公开(公告)日：2014-08-14

申请号：US14127416

申请日：2012-06-22

Applicant: Bruno Robert ,  Benedicte Fauvel ,  Gwenael Cheve ,  Aziz Yasri ,  Christel Larbouret ,  Wilhem Leconet ,  Thierry Chardes ,  Christian Larroque ,  Andre Pelegrin

Inventor： Bruno Robert ,  Benedicte Fauvel ,  Gwenael Cheve ,  Aziz Yasri ,  Christel Larbouret ,  Wilhem Leconet ,  Thierry Chardes ,  Christian Larroque ,  Andre Pelegrin

IPC: C07K16/28 ,  G01N33/68 ,  G01N33/574

CPC classification number: C07K16/28 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57492 ,  G01N33/6872

Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.

Abstract translation: 本发明涉及抗Ax1抗体及其在诊断和治疗方法中的用途。 更具体地说，本发明涉及对Ax1具有特异性的单克隆抗体，其包含H-CDR1区中包含SEQ ID NO：2的重链可变区，H-CDR2区中的SEQ ID NO：3和SEQ ID NO： 4在H-CDR3区域; 以及包含L-CDR1区中的SEQ ID NO：6，L-CDR2区的SEQ ID NO：7和L-CDR3区的SEQ ID NO：8的轻链可变区。 所述单克隆抗体通过SEQ ID NO：9和SEQ ID NO：10与Ax1的细胞外结构域结合。

公开(公告)号：US09249228B2

公开(公告)日：2016-02-02

申请号：US14127415

申请日：2012-06-22

Applicant: Bruno Robert ,  Benedicte Fauvel ,  Gwenael Cheve ,  Aziz Yasri ,  Christel Larbouret ,  Wilhem Leconet ,  Thierry Chardes ,  Christian Larroque ,  Andre Pelegrin

Inventor： Bruno Robert ,  Benedicte Fauvel ,  Gwenael Cheve ,  Aziz Yasri ,  Christel Larbouret ,  Wilhem Leconet ,  Thierry Chardes ,  Christian Larroque ,  Andre Pelegrin

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  C07K16/40 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/30 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57492

Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.

Abstract translation: 本发明涉及抗Ax1抗体及其在诊断和治疗方法中的用途。 更具体地说，本发明涉及对Ax1具有特异性的单克隆抗体，其包含H-CDR1区中包含SEQ ID NO：2的重链可变区，H-CDR2区中的SEQ ID NO：3和SEQ ID NO： 4在H-CDR3区域; 以及包含L-CDR1区中的SEQ ID NO：6，L-CDR2区的SEQ ID NO：7和L-CDR3区的SEQ ID NO：8的轻链可变区。 所述单克隆抗体通过SEQ ID NO：9，SEQ ID NO：10和SEQ ID NO：11结合Ax1的细胞外结构域。